|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer显示文摘 | Schlumberger MJ Elisei R Bastholt L | 2009 | J Clin Oncol2009，27，23： | 1 |
| 2 | Papillary thyroid carcinoma in Denmark 1996-2008:An investigation of changes in incidence显示文摘 | Londero SC Krogdahl A Bastholt L | | 0，，01： | 1 |
| 3 | Phase II,open-label,randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma显示文摘 | KIRKWOOD J M BASTHOLT L ROBERT C | | 0，，02： | 1 |
| 4 | A placebo- controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer 显示文摘 | NYGAARD B BASTHOLT L BENNEDBCEK F N | 2013 | Eur Thyroid J2013，2，3： | 1 |
| 5 | Esthesioneu-roblastoma-what is the optimal treatment? 显示文摘 | Eriksen JG Bastholt L Krogdahl AS | 2000 | Acta On-col2000，39，2： | 1 |
| 6 | Two different du-rations of adjuvant therapy with intermediate-dose inter-feron alfa-2b in patients with high-risk melanoma(NordicIFN trial) : a randomised phase 3 trial显示文摘 | Hansson J Aamdal S?Bastholt L | 2011 | Lancet Oncol2011，12，2： | 1 |
| 7 | Papillary thyroid microcarcinoma in Denmark 1996-2008: A national study of epidemiology and clinical significance 显示文摘 | Londero S C Krogdahl A Bastholt L | 2013 | Thyroid2013，23，9： | 1 |
| 8 | Vandet- anib in locally advanced or Metastatic differentiated thyroid canc- er (papillary or follicular; DTC) : a randomized, double-blind phase Ⅱ trial显示文摘 | LEBOULLEUX S BASTHOLT L KRAUSE TM | 2010 | Ann Oncol2010，21，8： | 1 |
| 9 | Phase Ⅱ,open-label,randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma显示文摘 | Kirkwood JM Bastholt L Robert C | 2012 | Clin Cancer Res2012，18，2： | 1 |
| 10 | Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a mndomised, double-blind, phase 2 trial显示文摘 | Leboulleux S Bastholt L Krause T | 2012 | Lancet Oneol2012，13，9： | 1 |
| 11 | Phase Ⅱ study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer显示文摘 | Schlumberger M J Elisei R Bastholt L | 2009 | J Clin Oncol2009，27，： | 1 |
| 12 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer显示文摘 | SCHLUMBERGER MJ ELISEI R BASTHOLT L | 2009 | J Clin Oncol2009，27，23： | 1 |
| 13 | Phase Ⅱ study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer 显示文摘 | Schlumberger M J Elisei R Bastholt L | 2009 | J Clin Oncol2009，27，23： | 1 |
| 14 | Papillarythyroid microcarcinoma in Denmark 1996-2008:A national study of epidemiology and clinical significance显示文摘 | LONDERO SC KROGDAHL A BASTHOLT L | 2013 | Thyroid2013，58，4： | 1 |
| 15 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer 显示文摘 | Schlumberger MJ Elisei R Bastholt L | 2009 | J Clin Oncol2009，27，23： | 1 |
| 16 | A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma显示文摘 | I Safwat A Schmidt H Bastholt L | 2005 | Radiother Oncol2005，77，2： | 1 |
| 17 | Papillary thyroid carcinoma in Denmark 1996-20081 an investigation of changes in incidence显示文摘 | LONDERO S C KROGDAHL A BASTHOLT L | 2013 | Cancer Epidemiol2013，37，1： | 1 |
| 18 | Papillary thyroid carcinoma in Denmark 1996-2008: an investigation of changes in incidence显示文摘 | Londero SC Krogdahl A Bastholt L | 2013 | Cancer Epidemiol2013，37，1： | 1 |
| 19 | Papillary thyroid in Denmark 1996-2008: A national study of epidemiology and clinical significance 显示文摘 | Londero SC Krogdah A Bastholt L | 2013 | Thyroid2013，23，9： | 1 |
| 20 | Vandetanib in locally advanced or metastatic differentiated thyroid cancer= a random- ised,double-hlind,phase 2 trial显示文摘 | Leboulleux S Bastholt L Krause T | 2012 | Lancet Oncol2012，13，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员